Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting. Issue 5 (7th February 2022)

• Record Type: Journal Article
• Authors: Dollfus, Catherine; Le Chenadec, Jérome; Mandelbrot, Laurent; Tubiana, Roland; Faye, Albert; Brossard, Maud; Frange, Pierre; Blanche, Stéphane; Warszawski, Josiane
• Is Part Of: Pediatric infectious disease journal. Volume 41:Issue 5(2022)
• Page Start: 420
• Page End: 423
• Publication Date: 2022-02-07
• Subjects: HIV1 -- perinatal transmission -- anemia -- nevirapine -- zidovudine; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000003478
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : In the ANRS French Perinatal Cohort, we compared outcomes in 830 HIV1-exposed infants who received either nevirapine (NVP) or zidovudine postnatal prophylaxis. At 1 month, anemia grade ≥2 was less frequent on NVP than zidovudine (2.9% vs. 8.0%; P = 0.01), favoring the use of NVP as a first choice prophylaxis in infants at low risk of HIV acquisition.